Genetics in medicine open · 2025
Rare variant genetic landscape of familial chylomicronemia syndrome (FCS) in the United Kingdom.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bashir Bilal, Forrester Natalie, Downie Paul, Marsh Sarah, Dent Carolyn, Wierzbicki Anthony S, Dawson Charlotte, Schofield Jonathan, Jenkinson Fiona, Mansfield Michael, Datta Dev, Delaney Hannah, Teoh Yee, Hamilton Paul, Cegla Jaimini, Ferdousi Maryam, Kamath Anoushka, Gupta Pankaj, Luvai Ahai, O'Sullivan Dawn, Mamood Deanna, Wang Jian, Durrington Paul N, Hegele Robert A, Soran Handrean
Аннотация
PURPOSE: Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder. This study aimed to analyze the genotype distribution of FCS-causing genes in the United Kingdom.
METHODS: Data were anonymously collated from 2 genetic testing laboratories providing national genetic diagnosis services for severe hypertriglyceridemia in the United Kingdom.
RESULTS: As of December 2023, 880 individuals underwent genetic testing for FCS. The mean (SD) age at the time of genetic testing was 42.5 (15.3) years. After genotyping, 12.9% of the individuals (n = 114) received a genetic diagnosis of FCS. The detection rate of variant-positive multifactorial chylomicronemia syndrome, ie, heterozygous for pathogenic/likely pathogenic (P/LP) variants in 1 of the 5 canonical genes was 11.4% (n = 100).Among 114 genetically proven FCS individuals, 52.6% (n = 60) had biallelic P/LP LPL variants (ie, LPL-FCS), 45.6% (n = 52) had biallelic non-LPL P/LP variants (ie, non-LPL-FCS) and 1.7% (n = 2) individuals were digenic. Among non-LPL-FCS (n = 52), the most common gene implicated was GPIHBP1 (42.3%, n = 22), followed by APOA5 (32.7%, n = 17), LMF1 (13.5%, n = 7) and APOC2 (11.5%, n = 6). Most variant-positive multifactorial chylomicronemia syndrome harbored P/LP variants in LPL (61%) or APOA5 (37%).The geographical distribution of FCS demonstrated regional variability, where the Northwest of England had the highest number of FCS cases per million population. Individuals of European geographic ancestry predominantly had LPL-FCS (60.9%); however, genotype was more diverse in individuals of non-European origin (LPL 47.1%, GPIHBP1 30.9%, APOA5 8.8%, LMF1 7.4%, and APOC2 4.4%). Variants in specific causal genes, GPIHBP1 and LMF1, were predominantly observed in non-European FCS individuals.
CONCLUSION: The genetic architecture of FCS in the United Kingdom is complex, with a substantial proportion affected by non-LPL FCS-causing genes. It also displays a significant regional and ethnic variations.
METHODS: Data were anonymously collated from 2 genetic testing laboratories providing national genetic diagnosis services for severe hypertriglyceridemia in the United Kingdom.
RESULTS: As of December 2023, 880 individuals underwent genetic testing for FCS. The mean (SD) age at the time of genetic testing was 42.5 (15.3) years. After genotyping, 12.9% of the individuals (n = 114) received a genetic diagnosis of FCS. The detection rate of variant-positive multifactorial chylomicronemia syndrome, ie, heterozygous for pathogenic/likely pathogenic (P/LP) variants in 1 of the 5 canonical genes was 11.4% (n = 100).Among 114 genetically proven FCS individuals, 52.6% (n = 60) had biallelic P/LP LPL variants (ie, LPL-FCS), 45.6% (n = 52) had biallelic non-LPL P/LP variants (ie, non-LPL-FCS) and 1.7% (n = 2) individuals were digenic. Among non-LPL-FCS (n = 52), the most common gene implicated was GPIHBP1 (42.3%, n = 22), followed by APOA5 (32.7%, n = 17), LMF1 (13.5%, n = 7) and APOC2 (11.5%, n = 6). Most variant-positive multifactorial chylomicronemia syndrome harbored P/LP variants in LPL (61%) or APOA5 (37%).The geographical distribution of FCS demonstrated regional variability, where the Northwest of England had the highest number of FCS cases per million population. Individuals of European geographic ancestry predominantly had LPL-FCS (60.9%); however, genotype was more diverse in individuals of non-European origin (LPL 47.1%, GPIHBP1 30.9%, APOA5 8.8%, LMF1 7.4%, and APOC2 4.4%). Variants in specific causal genes, GPIHBP1 and LMF1, were predominantly observed in non-European FCS individuals.
CONCLUSION: The genetic architecture of FCS in the United Kingdom is complex, with a substantial proportion affected by non-LPL FCS-causing genes. It also displays a significant regional and ethnic variations.